A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

被引：48

作者：

Wu, Xiujuan ^{[1
]}

Tang, Peng ^{[1
]}

Li, Shifei ^{[1
]}

Wang, Shushu ^{[1
]}

Liang, Yueyang ^{[1
]}

Zhong, Ling ^{[1
]}

Ren, Lin ^{[1
]}

Zhang, Ting ^{[1
]}

Zhang, Yi ^{[1
]}

机构：

[1] Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China

来源：

NATURE COMMUNICATIONS | 2018年 / 9卷

关键词：

PATHOLOGICAL COMPLETE RESPONSE; ARTERIAL CHEMOEMBOLIZATION; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; DOCETAXEL; CARBOPLATIN; EPIRUBICIN; PACLITAXEL; CISPLATIN; DOXORUBICIN;

D O I：

10.1038/s41467-018-03210-2

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.

引用

页数：8

共 50 条

[41] Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study [J].

Li Yanwei ;

Feng, He ;

Ren, Peng ;

Yue, Jie ;

Zhang, Wencheng ;

Tang, Peng ;

Shang, Xiaobin ;

Pang, Qingsong ;

Liu, Dongying ;

Chen, Chuangui ;

Pan, Zhanyu ;

Tao, Yu Zhen .

ONCOLOGIST, 2020, 25 (10) :E1464-E1472

[42] An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer [J].

Patil, Pradnya Dinkar ;

Shapiro, Marc ;

Sadraei, Nooshin Hashemi ;

Pennell, Nathan A. .

ONCOLOGIST, 2019, 24 (04) :457-E126

[43] Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial [J].

Li, Junjie ;

Yu, Keda ;

Pang, Da ;

Wang, Changqin ;

Jiang, Jun ;

Yang, Suisheng ;

Liu, Yunjiang ;

Fu, Peifen ;

Sheng, Yuan ;

Zhang, Guojun ;

Cao, Yali ;

He, Qi ;

Cui, Shude ;

Wang, Xijing ;

Ren, Guosheng ;

Li, Xinzheng ;

Yu, Shiyou ;

Liu, Pengxi ;

Qu, Xiang ;

Tang, Jinhai ;

Wang, Ouchen ;

Fan, Zhimin ;

Jiang, Guoqin ;

Zhang, Jin ;

Wang, Jiandong ;

Zhang, Hongwei ;

Wang, Shui ;

Zhang, Jianguo ;

Jin, Feng ;

Rao, Nanyan ;

Ma, Binlin ;

He, Pingqing ;

Xu, Binghe ;

Zhuang, Zhigang ;

Wang, Jianfeng ;

Sun, Qiang ;

Guo, Xiaofeng ;

Mo, Miao ;

Shao, Zhimin .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) :1774-+

[44] Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial [J].

Cortes, Javier ;

Hudgens, Stacie ;

Twelves, Chris ;

Perez, Edith A. ;

Awada, Ahmad ;

Yelle, Louise ;

McCutcheon, Susan ;

Kaufman, Peter A. ;

Forsythe, Anna ;

Velikova, Galina .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) :509-520

[45] Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer [J].

Kosaka, Yoshimasa ;

Saeki, Toshiaki ;

Takano, Toshimi ;

Aruga, Tomoyuki ;

Yamashita, Toshinari ;

Masuda, Norikazu ;

Koibuchi, Yukio ;

Osaki, Akihiko ;

Watanabe, Junichiro ;

Suzuki, Ryu .

INTERNATIONAL JOURNAL OF NANOMEDICINE, 2022, 17 :4567-4578

[46] Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial [J].

Zhou, Jian-Guo ;

Zhou, Nan-Jing ;

Zhang, Qiong ;

Feng, Yao-yao ;

Zhou, Hang .

TRIALS, 2018, 19

[47] Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08) [J].

Ruhstaller, T. ;

Thuss-Patience, P. ;

Hayoz, S. ;

Schacher, S. ;

Knorrenschild, J. R. ;

Schnider, A. ;

Plasswilm, L. ;

Budach, W. ;

Eisterer, W. ;

Hawle, H. ;

Mariette, C. ;

Hess, V. ;

Mingrone, W. ;

Montemurro, M. ;

Girschikofsky, M. ;

Schmidt, S. C. ;

Bitzer, M. ;

Bedenne, L. ;

Brauchli, P. ;

Stahl, M. .

ANNALS OF ONCOLOGY, 2018, 29 (06) :1386-1393

[48] Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial [J].

Marron, Thomas U. ;

Fiel, Maria Isabel ;

Hamon, Pauline ;

Fiaschi, Nathalie ;

Kim, Edward ;

Ward, Stephen C. ;

Zhao, Zhen ;

Kim, Joel ;

Kennedy, Paul ;

Gunasekaran, Ganesh ;

Tabrizian, Parissa ;

Doroshow, Deborah ;

Legg, Meredith ;

Hammad, Ashley ;

Magen, Assaf ;

Kamphorst, Alice O. ;

Shareef, Muhammed ;

Gupta, Namita T. ;

Deering, Raquel ;

Wang, Wei ;

Wang, Fang ;

Thanigaimani, Pradeep ;

Mani, Jayakumar ;

Troncoso, Leanna ;

Tabachnikova, Alexandra ;

Chang, Christie ;

Akturk, Guray ;

Buckup, Mark ;

Hamel, Steven ;

Ioannou, Giorgio ;

Hennequin, Clotilde ;

Jamal, Hajra ;

Brown, Haley ;

Bonaccorso, Antoinette ;

Labow, Daniel ;

Sarpel, Umut ;

Rosenbloom, Talia ;

Sung, Max W. ;

Kou, Baijun ;

Li, Siyu ;

Jankovic, Vladimir ;

James, Nicola ;

Ham, Sara C. ;

Cheung, Hung Kam ;

Sims, Jennifer S. ;

Miller, Elizabeth ;

Bhardwaj, Nina ;

Thurston, Gavin ;

Lowy, Israel ;

Gnjatic, Sacha .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03) :219-229

[49] Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial [J].

Hurvitz, Sara A. ;

Martin, Miguel ;

Symmans, W. Fraser ;

Jung, Kyung Hae ;

Huang, Chiun-Sheng ;

Thompson, Alastair M. ;

Harbeck, Nadia ;

Valero, Vicente ;

Stroyakovskiy, Daniil ;

Wildiers, Hans ;

Campone, Mario ;

Boileau, Jean-Francois ;

Beckmann, Matthias W. ;

Afenjar, Karen ;

Fresco, Rodrigo ;

Helms, Hans-Joachim ;

Xu, Jin ;

Lin, Yvonne G. ;

Sparano, Joseph ;

Slamon, Dennis .

LANCET ONCOLOGY, 2018, 19 (01) :115-126

[50] An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021) [J].

Lee, Shin-Wha ;

Kim, Yong-Man ;

Cho, Chi Heum ;

Kim, Young Tae ;

Kim, Seok Mo ;

Hur, Soo Young ;

Kim, Jae-Hoon ;

Kim, Byoung-Gie ;

Kim, Seung-Cheol ;

Ryu, Hee-Sug ;

Kang, Soon Beom .

CANCER RESEARCH AND TREATMENT, 2018, 50 (01) :195-203

← 1 2 3 4 5 →